Reports Q3 revenue $159,000, consensus $3.28M. “Silence continues to focus on operational execution, highlighted by the rapid achievement of full enrollment in our ongoing SANRECO Phase 2 study of divesiran, our first-in-class siRNA for PV,” said Craig Tooman, President and Chief Executive Officer at Silence. “We believe the positive momentum in our divesiran PV program, combined with exciting advancements in our early-stage pipeline, positions us well for both near and long-term value creation. We are looking forward to a strong finish to the year and meaningful pipeline catalysts ahead in 2026.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLN:
- Silence Therapeutics Completes Enrollment for Phase 2 Study
- Silence Therapeutics completes patient enrollment in SANRECO
- Silence Therapeutics: Promising mRNAi GOLD Platform and Strategic Initiatives Drive Buy Rating
- Silence Therapeutics: Strong Growth Potential with Promising Clinical Advances and Strategic Collaborations